These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 16383230)

  • 1. Psychopathological and cognitive correlates of tardive dyskinesia in patients treated with neuroleptics.
    Wonodi I; Hong LE; Thaker GK
    Adv Neurol; 2005; 96():336-49. PubMed ID: 16383230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of tardive dyskinesia in affective disorder patients.
    Yassa R; Ghadirian AM; Schwartz G
    J Clin Psychiatry; 1983 Nov; 44(11):410-2. PubMed ID: 6139365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focus on lower risk of tardive dyskinesia with atypical antipsychotics.
    Nasrallah HA
    Ann Clin Psychiatry; 2006; 18(1):57-62. PubMed ID: 16517454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
    Tarsy D; Baldessarini RJ
    Mov Disord; 2006 May; 21(5):589-98. PubMed ID: 16532448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Two cases of tardive Tourette syndrome].
    Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(5):459-65. PubMed ID: 16869393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification and treatment of tardive syndromes.
    Fernandez HH; Friedman JH
    Neurologist; 2003 Jan; 9(1):16-27. PubMed ID: 12801428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive impairment in tardive dyskinesia.
    Wegner JT; Kane JM; Weinhold P; Woerner M; Kinon B; Lieberman J
    Psychiatry Res; 1985 Dec; 16(4):331-7. PubMed ID: 2868476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tardive dyskinesia: review of the literature].
    Carta MG; Hardoy MC; Dell'Osso L; Carpiniello B
    Clin Ter; 2004 Apr; 155(4):127-33. PubMed ID: 15354761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
    Cortese L; Caligiuri MP; Williams R; Schieldrop P; Manchanda R; Malla A; Harricharan R
    J Clin Psychopharmacol; 2008 Feb; 28(1):69-73. PubMed ID: 18204344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between neuroleptic extrapyramidal syndromes and patients' all-cause mortality.
    Modestin J; Vogt Wehrli M; Stephan PL; Agarwalla P
    Pharmacopsychiatry; 2009 Mar; 42(2):57-60. PubMed ID: 19308879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.
    Inada T; Koga M; Ishiguro H; Horiuchi Y; Syu A; Yoshio T; Takahashi N; Ozaki N; Arinami T
    Pharmacogenet Genomics; 2008 Apr; 18(4):317-23. PubMed ID: 18334916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients.
    Zai CC; Tiwari AK; Basile V; De Luca V; Müller DJ; King N; Voineskos AN; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Kennedy JL
    Pharmacogenomics J; 2009 Jun; 9(3):168-74. PubMed ID: 19238168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.
    Lee HJ; Kang SG; Choi JE; Paik JW; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
    Neuropsychobiology; 2007; 55(1):47-51. PubMed ID: 17556853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic-induced tardive movement disorders: a series of twelve cases.
    Kasantikul D; Kanchanatawan B
    J Med Assoc Thai; 2007 Jan; 90(1):188-94. PubMed ID: 17621754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland].
    Gałecki P; Pietras T; Szemraj J
    Psychiatr Pol; 2006; 40(5):937-48. PubMed ID: 17217237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study.
    Tenback DE; van Harten PN; Slooff CJ; van Os J;
    Compr Psychiatry; 2007; 48(5):436-40. PubMed ID: 17707251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Informing patients about tardive dyskinesia: A survey of clinicians' attitudes in three countries.
    Laugharne J; Davies A; Arcelus J; Bouman WP
    Int J Law Psychiatry; 2004; 27(1):101-8. PubMed ID: 15019771
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.